Zobrazeno 1 - 10
of 61
pro vyhledávání: '"Jochen Kuhlmann"'
Publikováno v:
Biomarker Insights, Vol 2, Pp 81-93 (2007)
Biomarkers are increasingly used to provide decision making data early in phase I by showing Proof of Mechanism or Proof of Concept (PoM/PoC). For antihypertensive agents, the administration of multiple doses (md) to hypertensive patients is assumed
Externí odkaz:
https://doaj.org/article/6fd1f83a21974703ab7cc51f2031e227
Autor:
Mario Caironi, Walter Thiel, Josef Brandt, Amaia Diaz de Zerio Mendaza, Florian Lombeck, Michael Sommer, Dominik Stegerer, Richard H. Friend, Christian Müller, Hartmut Komber, Daniele Fazzi, Diego Nava, Jochen Kuhlmann, Karen Strassel
Publikováno v:
Advanced Energy Materials. 6
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1b8e99649fa28d13bede8b6098bf7e33
https://doi.org/10.1002/aenm.201670123
https://doi.org/10.1002/aenm.201670123
Autor:
Florian Lombeck, Hartmut Komber, Daniele Fazzi, Diego Nava, Jochen Kuhlmann, Dominik Stegerer, Karen Strassel, Josef Brandt, Amaia Diaz de Zerio Mendaza, Christian Müller, Walter Thiel, Mario Caironi, Richard Friend, Michael Sommer
This is a non-edited copy of the pre-print version of the paper Avanced Energy Materials 6 (2016)1601232
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2659::0d68b45a5c7cec371fc30973c31834d1
https://zenodo.org/record/3991779
https://zenodo.org/record/3991779
Autor:
Jochen Kuhlmann
Publikováno v:
Arzneimittelforschung. 54:251-258
To improve the transition from research to development a critical evaluation of the individual project by research and disease area teams is required to include input from pharmacology, toxicology, pharmacokinetics, galenics, clinical pharmacology, c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9cefdee3c6c30db7937886b9480bfb3b
https://doi.org/10.1055/s-0031-1296967
https://doi.org/10.1055/s-0031-1296967
Publikováno v:
Pharmaceutical Research. 22:1432-1437
In recent years, pharmacokinetic/pharmacodynamic (PK/PD) modeling has developed from an empirical descriptive discipline into a mechanistic science that can be applied at all stages of drug development. Mechanism-based PK/PD models differ from empiri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18d46cb20a68cfd450ae4fb3b3756280
https://doi.org/10.1007/s11095-005-5882-3
https://doi.org/10.1007/s11095-005-5882-3
Publikováno v:
Progress in Neuro-Psychopharmacology and Biological Psychiatry. 29:549-556
Assessment of cerebral blood flow velocities (CBFV) can be used as a non-invasive tool to evaluate specific drug effects, like caffeine (CAF), acetazolamide (AA) as well as cognition. Their influences on each others CBFV were evaluated in detail, usi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b1851c627a1c67b2ad1e568bcde1df09
https://doi.org/10.1016/j.pnpbp.2005.01.006
https://doi.org/10.1016/j.pnpbp.2005.01.006
Autor:
Jochen Kuhlmann, Walter Puls
The prevalence of diabetes continues to increase worldwide. Traditionally, diabetes in its adult form has not been considered a serious life-threatening disease. This attitude needs to be changed because the complications asso ciated with the adult
It has been over 30 years since the first clinically important member of the quinolone class, nalidixic acid, was introduced into medical practice. The modification produced in the quinolone nucleus by introducing a fluorine at the 6-position led to
Autor:
Mario Caironi, Richard H. Friend, Amaia Diaz de Zerio Mendaza, Walter Thiel, Josef Brandt, Michael Sommer, Dominik Stegerer, Florian Lombeck, Christian Müller, Hartmut Komber, Jochen Kuhlmann, Daniele Fazzi, Karen Strassel, Diego Nava
Publikováno v:
Advanced Energy Materials
The photophysical properties and solar cell performance of the classical donor-acceptor copolymer PCDTBT(poly(N-9-heptadecanyl-2,7-carbazole-alt -5,5-(4,7-di-2-thienyl-2,1,3-benzothiadiazole))) in relation to unintentionally formed main chain defects
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29da0e7a32a7e3c8d34054f212d16a80
https://doi.org/10.1002/aenm.201601232
https://doi.org/10.1002/aenm.201601232
Autor:
Georg Wensing, Jochen Kuhlmann
Publikováno v:
Current clinical pharmacology. 1(2)
Selecting, evaluating and applying biomarkers in drug discovery and exploratory drug development do substantially shorten the time to reach a critical decision point. Biomarkers are most useful in the early phase of clinical development when measurem
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21245bc9a1594024251d6bdb4c49e267
https://pubmed.ncbi.nlm.nih.gov/18666370
https://pubmed.ncbi.nlm.nih.gov/18666370